SecurityTGXSF / Tigenix Sa (88675R109)
Institutional Owners9
Institutional Shares574,080
Institutional Value$ 24,536,000 USD

Institutional Stock Ownership and Shareholders()

TGXSF / Tigenix Sa Institutional Ownership

Tigenix Sa (OTC:TGXSF) has 9 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 574,080 shares. Largest shareholders include Hillhouse Capital Management, Ltd., Millennium Management Llc, Diversified Trust Co, Renaissance Technologies LLC, Gabelli Securities, Inc., Deutsche Bank Ag\, Morgan Stanley, UBS Group AG, and Bank Of America Corp /de/.
Tigenix Sa (OTC:TGXSF) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/tgxsf"><img src="https://images.fintel.io/us-tgxsf-so.png" alt="TGXSF / Tigenix Sa Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-10-26 13F-HR Acrospire Investment Management LLC 1,156 0 -100.00 26 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 3,600 1,400 -61.11 82 60 -26.83
2018-05-15 13F-HR JANE STREET GROUP, LLC 16,423 0 -100.00 376 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 255 255 0.00 6 11 83.33
2018-05-15 13F-HR UBS Group AG 843 539 -36.06 19 23 21.05
2018-05-14 13F-HR Renaissance Technologies LLC 6,800 294
2018-05-15 13F-HR DEUTSCHE BANK AG\ 5,300 4,700 -11.32 121 202 66.94
2018-06-01 13F-HR Diversified Trust Co 10,073 10,073 0.00 231 435 88.31
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 62,429 61,478 -1.52 1,430 2,626 83.64
2018-05-15 13F-HR Hillhouse Capital Management, Ltd. 483,870 483,870 0.00 11,052 20,671 87.03
2018-05-09 13F-HR GABELLI SECURITIES, INC. 4,965 214

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix | Business Wire

2018-05-23 businesswire
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced information related to its previously announced and ongoing tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”) of TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) that are not yet owned by Takeda and its affiliates, in two separate, but concurrent and related offers in Belgium (the “Belgian Offer”) and in the United States (the “U.

Shire bid marks Takeda’s latest and biggest push for global status

2018-04-26 japantimes.co.jp
Takeda Pharmaceutical Co. Ltd..’s $64 billion bid for London-listed rare-disease specialist Shire PLC bolsters its credentials as Japan’s most outward-facing drugs firm, a mold-breaking image that has been more than a decade in the making. (3-0)

Shire bid marks Takeda's latest - and biggest - push for global status

2018-04-25 reuters
TOKYO (Reuters) - Takeda Pharmaceutical Co Ltd’s (4502.T) $64 billion bid for London-listed rare disease specialist Shire Plc (SHP.L) bolsters its credentials as Japan’s most outward facing drugs firm, a mould-breaking image that has been more than a decade in the making. (3-0)

Takeda Announces Voluntary and Conditional Public Takeover Bid for Outstanding Shares, Warrants and American Depositary Shares of TiGenix NV to Commence April 30, 2018 | Business Wire

2018-04-25 businesswire
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the first acceptance period of its previously announced tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”) of TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) that are not yet owned by Takeda and its affiliates, at an acquisition price of EUR 1.

UPDATED: Takeda Pharma and Shire Come Back to the Negotiating Table and Offer is Set at $64 Billion

2018-04-25 biospace
Takeda Pharmaceutical has come back with an improved bid for Shire for $64 billion, making it the fifth round of talks. Shire is willing to recommend to the board to accept the offer with an extended deal deadline of May 8. (5-0)

CUSIP: 88675R109